Collegium Pharmaceutical ...

30.43
0.38 (1.26%)
At close: Mar 24, 2025, 3:59 PM
30.27
-0.51%
After-hours: Mar 24, 2025, 07:55 PM EDT
1.26%
Bid 27.58
Market Cap 958.1M
Revenue (ttm) 619.77M
Net Income (ttm) 67.91M
EPS (ttm) 1.86
PE Ratio (ttm) 16.36
Forward PE 4.94
Analyst Buy
Ask 32.97
Volume 456,363
Avg. Volume (20D) 419,044
Open 30.43
Previous Close 30.05
Day's Range 29.42 - 30.84
52-Week Range 27.27 - 42.29
Beta 0.99

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

Sector Healthcare
IPO Date May 7, 2015
Employees 357
Stock Exchange NASDAQ
Ticker Symbol COLL
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 44.59% from the latest price.

Stock Forecasts

Next Earnings Release

Collegium Pharmaceutical Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+2.22%
Collegium Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription
3 weeks ago
+0.25%
Collegium Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.